Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Elisabetta Patorno, Ajinkya Pawar, Deborah J. Wexler, et al.
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 3, pp. 442-454
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA1c Levels
Elvira D’Andrea, Deborah J. Wexler, Seoyoung C. Kim, et al.
JAMA Internal Medicine (2023) Vol. 183, Iss. 3, pp. 242-242
Open Access | Times Cited: 54
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
Guntram Schernthaner, Naim Shehadeh, Ametov As, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 127
Unlocking the power of empagliflozin: Rescuing inflammation in hyperglycaemia‐ exposed human cardiomyocytes through comprehensive multi‐level analysis
Rosaria Benedetti, Ugo Chianese, Chiara Papulino, et al.
European Journal of Heart Failure (2025)
Open Access | Times Cited: 1
Incident heart failure, arrhythmias and cardiovascular outcomes with sodium‐glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record database
Ameenathul M. Fawzy, José Miguel Rivera‐Caravaca, Paula Underhill, et al.
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 2, pp. 602-610
Open Access | Times Cited: 30
Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?
André Scheen, Fabrice Bonnet
Diabetes & Metabolism (2023) Vol. 49, Iss. 2, pp. 101419-101419
Open Access | Times Cited: 20
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Avraham Karasik, Stefanie Lanzinger, Elise Tan, et al.
Diabetes & Metabolism (2023) Vol. 49, Iss. 2, pp. 101418-101418
Open Access | Times Cited: 19
Practical considerations for the use of SGLT‐2 inhibitors in the Asia–Pacific countries—An expert consensus statement
Adrian Liew, Aida Lydia, Bien J. Matawaran, et al.
Nephrology (2023) Vol. 28, Iss. 8, pp. 415-424
Open Access | Times Cited: 17
Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review
Thahesh Tharmaraja, Jamie Sin Ying Ho, Ching‐Hui Sia, et al.
Therapeutic Advances in Chronic Disease (2022) Vol. 13, pp. 204062232210869-204062232210869
Open Access | Times Cited: 24
Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome
Hiroki Akiyama, Akihiro Nishimura, Naru Morita, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 14
Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis
Jui‐Yi Chen, Heng‐Chih Pan, Chih‐Chung Shiao, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 14
Effectiveness and safety of empagliflozin: final results from the EMPRISE study
Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiß, et al.
Diabetologia (2024) Vol. 67, Iss. 7, pp. 1328-1342
Closed Access | Times Cited: 5
A systematic literature review on the burden of diabetic ketoacidosis in type 2 diabetes mellitus
Carol Wysham, Anila Bindal, Fleur Levrat‐Guillen, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
Chun Xing Li, Tian Tian Liu, Qian Zhang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 10
The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review
André Scheen
Expert Review of Endocrinology & Metabolism (2023) Vol. 18, Iss. 4, pp. 271-282
Closed Access | Times Cited: 9
Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes—A Systematic Review
Rikke Viggers, Nicklas H. Rasmussen, Peter Vestergaard
JBMR Plus (2023) Vol. 7, Iss. 11
Open Access | Times Cited: 9
Prevalence of sodium-glucose transporter 2 inhibitor-associated diabetic ketoacidosis in real-world data: A systematic review and meta-analysis
Bassel Al-Hindi, Mohammed A. Mohammed, Ernest Mangantig, et al.
Journal of the American Pharmacists Association (2023) Vol. 64, Iss. 1, pp. 9-26.e6
Closed Access | Times Cited: 9
Kidney and Cardiovascular Effectiveness of Empagliflozin Compared With Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes
Daniel Edmonston, Hillary Mulder, Elizabeth Lydon, et al.
The American Journal of Cardiology (2024) Vol. 221, pp. 52-63
Closed Access | Times Cited: 3
Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes
Helen Tesfaye, Julie M. Paik, Miin Roh, et al.
JAMA Ophthalmology (2024)
Closed Access | Times Cited: 3
Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes: Post‐authorization safety study based on multinational cohorts
Cristina Rebordosa, Reimar W. Thomsen, Arlene Tave, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 4, pp. 1291-1304
Open Access | Times Cited: 2
Comparative effectiveness of Empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care
Rishi Desai, Robert J. Glynn, Brendan M. Everett, et al.
American Heart Journal (2022) Vol. 254, pp. 203-215
Closed Access | Times Cited: 12
Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study
Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, et al.
Expert Opinion on Drug Safety (2022) Vol. 21, Iss. 10, pp. 1315-1328
Open Access | Times Cited: 11
Rates of diabetic ketoacidosis with empagliflozin use during hospitalization for acute heart failure
Cheng‐Wei Huang, Janet Lee, Ming‐Sum Lee
Journal of Hospital Medicine (2024) Vol. 19, Iss. 2, pp. 116-119
Closed Access | Times Cited: 2
Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
Ja Young Jeon, Dae Jung Kim
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 5, pp. 837-846
Closed Access | Times Cited: 2
Cardiovascular and renal outcomes with SGLT2 inhibitors: Real-life observational studies in older patients with type 2 diabetes
André Scheen
Diabetes Epidemiology and Management (2023) Vol. 10, pp. 100135-100135
Open Access | Times Cited: 6
Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: A sub‐analysis of the DIVERSITY‐CVR study
Kota Takuma, Ayako Fuchigami, Fumika Shigiyama, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 8, pp. 2131-2141
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top